zurück

Upadacitinib (new indication: ulcerative colitis, pretreated patients)

 

Subject:

  • Active Sustance: Upadacitinib
  • Name: Rinvoq®
  • Therapeutic area: Ulcerative colitis
  • Pharmaceutical company: AbbVie Deutschland GmbH & Co. KG

 

Time table:

  • Start: 01.09.2022
  • Final decision by G-BA: 16.02.2023

 

Final decision:

  1. Patients, who have had an inadequate response, no longer respond to conventional therapy, or have an intolerance or contraindication: No additional benefit proved
  2. Patients, who have had an inadequate response, no longer respond, or are intolerant to a biologic (TNF-α antagonist or integrin inhibitor or interleukin inhibitor): No additional benefit proved